New Patents Issued to Diffusion Pharmaceuticals
Lead drug trans sodium crocetinate receives new patent protection through 2027
Diffusion Pharmaceuticals LLC announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, composition, and methods of use relating to Diffusion's lead molecule, trans sodium crocetinate (TSC), as well as the entire family of first-in-class new chemical entities in the Company’s pipeline of therapeutic candidates. Diffusion Pharmaceuticals is commercializing this family of first-in-class drugs to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level. Enrollment is currently underway in a multi-center Phase I/II study of TSC for the improved treatment of newly diagnosed primary brain cancer patients.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.